IPP Bureau
Sputnik Light in India by December: RDIF
By IPP Bureau - November 25, 2021
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster
Cadila partners with Enzychem of South Korea to manufacture ZyCoV-D
By IPP Bureau - November 25, 2021
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
ICMR approves Meril’s Rapid Antigen Test kit
By IPP Bureau - November 25, 2021
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
Bharat Biotech updates on the Lancet study on Covaxin efficacy
By IPP Bureau - November 25, 2021
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
.jpg "Air pollution reduces life expectancy by eight years in India")
Air pollution reduces life expectancy by eight years in India
By IPP Bureau - November 25, 2021
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
Gastrointestinal disorders increasing in India
By IPP Bureau - November 25, 2021
It is estimated that one-third of our country’s population has some form of these disorders
Boehringer Ingelheim India enters Guinness World Records through its Stroke campaign
By IPP Bureau - November 25, 2021
The week-long campaign received a record 17.691 pledges
ADB approves US $ 1.5 bn for Covid-19 vaccines in India
By IPP Bureau - November 25, 2021
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
ACG to set up Asia's largest capsule plant in Maharashtra
By IPP Bureau - November 24, 2021
Officials from ACG signed the MoU with the Maharashtra government for the Rs 600 crore investment in the backward region of Marathwada
Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate
By IPP Bureau - November 24, 2021
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
U.S. FDA approves first treatment for drug-resistant post-transplant infection
By IPP Bureau - November 24, 2021
The approval is for Cytomegalovirus, a type of Herpes virus
Vivera announces launch of new testing software, LabPort
By IPP Bureau - November 24, 2021
Featuring identity verification using artificial intelligence (AI), LabPort was designed to facilitate immediate results reporting for diagnostic testing even in high-volume, field-based testing environments
Serum Life Sciences invests US $ 10 million in GreenLight Biosciences
By IPP Bureau - November 24, 2021
GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
Ipca Laboratories acquires 26 % stake in Lyka Labs, makes open offer
By IPP Bureau - November 24, 2021
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
Fortis Escorts Faridabad introduces Cryo technique to treat lung cancer
By IPP Bureau - November 24, 2021
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
